Home Anti-nucleosome, anti-chromatin, anti-dsDNA and anti-histone antibody reactivity in systemic lupus erythematosus
Article
Licensed
Unlicensed Requires Authentication

Anti-nucleosome, anti-chromatin, anti-dsDNA and anti-histone antibody reactivity in systemic lupus erythematosus

  • Concepción González , Belen Garcia-Berrocal , Oscar Herráez , José Alejandro Navajo and José ManuelGonzález-Buitrago
Published/Copyright: June 1, 2005

Abstract

Anti-nucleosome (anti-chromatin) antibodies play a key role in the pathogenesis of systemic lupus erythematosus (SLE). The objective of the present study was to determine the clinical significance of anti-nucleosome (anti-chromatin) antibodies, anti-dsDNA antibodies and anti-histone antibodies in patients with SLE in relation to patients with positive nuclear antibodies and healthy controls. We measured anti-nucleosome (anti-chromatin) antibodies, anti-dsDNA antibodies and anti-histone antibodies in 70 patients with SLE, 35 antinuclear antibody (ANA)-positive subjects without autoimmune disease and 35 blood donors. All antibodies were determined by enzyme-linked immunosorbent assay (ELISA). We obtained the receiver operating caracteristic (ROC) curve and the area under the curve (AUC) for each autoantibody. Likewise, we obtained the sensitivity, specificity and positive and negative likelihood ratios for each autoantibody. The highest AUC was obtained for anti-nucleosome (0.898) and the lowest AUC for a kit for anti-dsDNA (0.725). Stratification of the control group (ANA-positive subjects without autoimmune disease and blood donors) produced significant changes in the AUCs; all AUCs decreased when ANA-positive patients without autoimmune disease were considered as controls and all AUCs increased when blood donors were considered as controls. These effects were less marked in anti-dsDNA antibodies. We observed discrepancies between kits (anti-nucleosome and anti-chromatin and two for anti-dsDNA). The highest sensitivity for SLE was obtained for anti-nucleosome antibodies (86%) and the highest specificity was obtained for anti-dsDNA antibodies (90%). In conclusion, anti-nucleosome and anti-chromatin kits show different degrees of clinical accuracy due to the cut-off selected by the manufacturer. Once the kits with the best performance and the optimal cut-offs have been selected, anti-nucleosome antibodies and anti-dsDNA antibodies provide similar information in established SLE.

Published Online: 2005-6-1
Published in Print: 2004-3-9

Copyright © 2004 by Walter de Gruyter GmbH & Co. KG

Articles in the same Issue

  1. Phage-displayed recombinant single-chain antibody fragments with high affinity for cholesteryl ester transfer protein (CETP): cDNA cloning, characterization and CETP quantification
  2. Stem cell factor and macrophage-colony stimulating factor in patients with pancreatic cancer
  3. Modulation of plasma fibrinogen levels in acute-phase response after hepatectomy
  4. Anti-nucleosome, anti-chromatin, anti-dsDNA and anti-histone antibody reactivity in systemic lupus erythematosus
  5. Expression of activation molecules in neutrophils, monocytes and lymphocytes from patients with unstable angina treated with stent implantation
  6. Acid ribonuclease and alkaline ribonuclease isoenzymes in plasma of patients with decreased glomerular filtration rate
  7. Is calcium oxalate nucleation in postprandial urine of males with idiopathic recurrent calcium urolithiasis related to calcium phosphate nucleation and the intensity of stone formation? Studies allowing insight into a possible role of urinary free citrate and protein
  8. Significance of consecutive international normalized ratio (INR) outcomes using statistical control rules in long-term anticoagulated patients. Optimization of laboratory monitoring and interpretation of borderline measurements
  9. Clinical trials and p-values, beware of the extremes
  10. Age dependence of serum β-N-acetylhexosaminidase (NAG) activity
  11. Elevated plasma total homocysteine in centenarians
  12. New methodology of influential point detection in regression model building for the prediction of metabolic clearance rate of glucose
  13. Intra-laboratory analytical variability of biochemical markers of fibrosis (Fibrotest) and activity (Actitest) and reference ranges in healthy blood donors
  14. The glutathione S-transferase polymorphisms in a control population and in Alzheimer's disease patients
  15. Near-patient testing for infection using urinalysis and immuno-chromatography strips
  16. Long-distance mountain biking does not disturb the measurement of total, free or complexed prostate-specific antigen in healthy men
  17. Development of a new colorimetric method for protein S activity measurement
  18. Re.: Correction to the IFCC primary reference method for the measurement of catalytic activity concentration of enzymes at 37C- part 2: reference procedure for the measurement of creatine kinase. Clin Chem Lab Med 2002;40:635-42
  19. Meetings and Awards
Downloaded on 11.9.2025 from https://www.degruyterbrill.com/document/doi/10.1515/CCLM.2004.049/html
Scroll to top button